{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:03:14Z","timestamp":1790892194210,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012581","name":"The Macula Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ajo.2025.08.034","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T08:15:50Z","timestamp":1755764150000},"page":"248-266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Clinical Efficacy of Switching to Faricimab in Treatment Resistant Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"280","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1257-0476","authenticated-orcid":false,"given":"CHARLES","family":"ZHANG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GEORGES","family":"ABOUKASM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DANIEL A","family":"LAI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NICHOLAS","family":"LEUNG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DANIEL","family":"ZHU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"THOMAS A","family":"ALBINI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NICOLAS A","family":"YANNUZZI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ajo.2025.08.034_bib0001","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1016\/j.ophtha.2019.09.024","article-title":"Age-related macular degeneration preferred practice pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ajo.2025.08.034_bib0002","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1001\/jamaophthalmol.2022.4401","article-title":"Prevalence of age-related macular degeneration in the US in 2019","volume":"140","author":"Rein","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2025.08.034_bib0003","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1080\/07853890600946724","article-title":"Age-related macular degeneration\u2013emerging pathogenetic and therapeutic concepts","volume":"38","author":"Gehrs","year":"2006","journal-title":"Ann Med"},{"key":"10.1016\/j.ajo.2025.08.034_bib0004","first-page":"1857","article-title":"Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review","volume":"10","author":"Yang","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ajo.2025.08.034_bib0005","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6835782","article-title":"Switch to Aflibercept in the treatment of neovascular AMD: long-term results","volume":"2017","author":"Neves Cardoso","year":"2017","journal-title":"J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2025.08.034_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajoint.2024.100049","article-title":"Short-term results with faricimab in neovascular age-related macular degeneration resistant to both ranibizumab and aflibercept","volume":"1","author":"Schneider","year":"2024","journal-title":"AJO Int"},{"issue":"9","key":"10.1016\/j.ajo.2025.08.034_bib0007","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.oret.2022.03.024","article-title":"Predominantly persistent intraretinal fluid in the comparison of age-related macular degeneration treatments trials","volume":"6","author":"Core","year":"2022","journal-title":"Ophthalmol Retina."},{"issue":"12","key":"10.1016\/j.ajo.2025.08.034_bib0008","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2025.08.034_bib0009","doi-asserted-by":"crossref","DOI":"10.1038\/srep29619","article-title":"Non-responsiveness to intravitreal aflibercept treatment in neovascular age-related macular degeneration: implications of serous pigment epithelial detachment","volume":"6","author":"Nagai","year":"2016","journal-title":"Scientific Reports"},{"issue":"7","key":"10.1016\/j.ajo.2025.08.034_bib0010","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2025.08.034_bib0011","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","article-title":"Faricimab: first approval","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ajo.2025.08.034_bib0012","article-title":"Anatomic outcomes with Faricimab vs Aflibercept in head-to-head dosing phase of the TENAYA\/LUCERNE trials in neovascular age-related macular degeneration","author":"Cheung","year":"2024","journal-title":"Ophthalmology"},{"issue":"17","key":"10.1016\/j.ajo.2025.08.034_bib0013","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","article-title":"The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results","volume":"37","author":"Khanani","year":"2023","journal-title":"Eye (Lond)"},{"issue":"1","key":"10.1016\/j.ajo.2025.08.034_bib0014","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.oret.2023.08.018","article-title":"Short-term outcomes of Faricimab in patients with neovascular age-related macular degeneration on prior anti-VEGF therapy","volume":"8","author":"Szigiato","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ajo.2025.08.034_bib0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/9781119536604.ch4","article-title":"Searching for and selecting studies","author":"Lefebvre","year":"2019","journal-title":"Cochrane Handbook for Systematic Rev Intervent"},{"key":"10.1016\/j.ajo.2025.08.034_bib0016","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ajo.2025.08.034_bib0017","article-title":"Durability and efficacy of Faricimab in treatment-resistant retinal edema utilizing \"real-world\" dosing regimens","volume":"2024","author":"Savant","year":"2024","journal-title":"J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2025.08.034_bib0018","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1167\/tvst.13.11.14","article-title":"Ocular pharmacokinetics of Faricimab following intravitreal administration in patients with retinal disease","volume":"13","author":"Diack","year":"2024","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.ajo.2025.08.034_bib0019","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.2147\/OPTH.S482948","article-title":"Real-world-data of treatment-na\u00efve and previously treated patients receiving up to 3 injections of Faricimab in neovascular age-related macular degeneration","volume":"18","author":"Kunzmann","year":"2024","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ajo.2025.08.034_bib0020","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.2147\/OPTH.S468458","article-title":"Evaluating Faricimab in treatment-naive Neovascular age related macular degeneration: a retrospective analysis of real-world data","volume":"18","author":"Modeste","year":"2024","journal-title":"Clinical ophthalmology (Auckland, NZ)"},{"issue":"6","key":"10.1016\/j.ajo.2025.08.034_bib0021","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.oret.2023.11.015","article-title":"Outcomes of treatment-resistant neovascular age-related macular degeneration switched from Aflibercept to Faricimab","volume":"8","author":"Raimondi","year":"2024","journal-title":"Ophthalmol Retina."},{"key":"10.1016\/j.ajo.2025.08.034_bib0022","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ajo.2025.08.034_bib0023","unstructured":"National Heart, Lung, and Blood Institute. Quality assessment tool for observational cohort and cross-sectional studies. Updated July 2021. https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"issue":"7650","key":"10.1016\/j.ajo.2025.08.034_bib0024","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.ajo.2025.08.034_bib0025","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1007\/s00417-024-06485-y","article-title":"Short-term outcomes of intravitreal faricimab for refractory neovascular age-related macular degeneration","volume":"262","author":"Aljundi","year":"2024","journal-title":"Graefe's Arch Clin Experiment Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.08.034_bib0026","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40942-025-00629-w","article-title":"Faricimab efficacy in type 1 macular neovascularization: aI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in na\u00efve and switch eyes","volume":"11","author":"Cattaneo","year":"2025","journal-title":"Int J Retina Vitreous"},{"issue":"4","key":"10.1016\/j.ajo.2025.08.034_bib0027","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/eye.2010.216","article-title":"Comparison of retinal thickness values and segmentation performance of different OCT devices in acute branch retinal vein occlusion","volume":"25","author":"Matt","year":"2011","journal-title":"Eye"},{"issue":"8","key":"10.1016\/j.ajo.2025.08.034_bib0028","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1097\/IAE.0000000000003194","article-title":"Retinal fluid and thickness AS measures of disease activity in neovascular age-related macular degeneration","volume":"41","author":"Kaiser","year":"2021","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.ajo.2025.08.034_bib0029","doi-asserted-by":"crossref","first-page":"8","DOI":"10.22336\/rjo.2020.3","article-title":"A meta-analysis to study the effect of pan retinal photocoagulation on retinal nerve fiber layer thickness in diabetic retinopathy patients","volume":"64","author":"Wadhwani","year":"2020","journal-title":"Rom J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.08.034_bib0031","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0002-9394(02)01825-1","article-title":"A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol","volume":"135","author":"Beck","year":"2003","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2025.08.034_bib0032","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s40123-024-01036-4","article-title":"One-year real-world outcomes of Intravitreal Faricimab for previously treated neovascular age-related macular degeneration","volume":"13","author":"Cancian","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.ajo.2025.08.034_bib0033","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/9781119536604.ch13","article-title":"Assessing risk of bias due to missing results in a synthesis","author":"Page","year":"2019","journal-title":"Cochrane Handbook Systematic Rev Intervent"},{"issue":"1","key":"10.1016\/j.ajo.2025.08.034_bib0034","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10792-024-03297-1","article-title":"Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration","volume":"44","author":"Aldhanhani","year":"2024","journal-title":"Int Ophthalmol"},{"issue":"16","key":"10.1016\/j.ajo.2025.08.034_bib0035","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1038\/s41433-024-03218-7","article-title":"Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy","volume":"38","author":"Goodchild","year":"2024","journal-title":"Eye"},{"issue":"5","key":"10.1016\/j.ajo.2025.08.034_bib0036","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/ceo.14335","article-title":"Retreatment interval lengthening achieved in two thirds of eyes with prolonged intensive anti-VEGF therapy for neovascular age-related macular degeneration after switching to faricimab","volume":"52","author":"Kenworthy","year":"2024","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2025.08.034_bib0037","doi-asserted-by":"crossref","DOI":"10.1038\/s41433-024-03583-3","article-title":"Analysis of quantitative OCT and SS-OCTA metrics three months after initiation of intravitreal faricimab for treatment-recalcitrant neovascular AMD","author":"Nadel","year":"2025","journal-title":"Eye"},{"issue":"4","key":"10.1016\/j.ajo.2025.08.034_bib0038","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.oret.2023.10.018","article-title":"Clinical outcomes of Faricimab in patients with previously treated neovascular age-related macular degeneration","volume":"8","author":"Pandit","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ajo.2025.08.034_bib0039","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.2147\/OPTH.S483563","article-title":"Outcomes after switching to Faricimab for refractive macular edema in treatment-experienced eyes with neovascular age-related macular degeneration","volume":"18","author":"Qaseem","year":"2024","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2025.08.034_bib0040","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3928\/23258160-20240410-04","article-title":"Faricimab in previously treated eyes with neovascular age-related macular degeneration: an assessment of durability and treatment outcomes","volume":"55","author":"Shaheen","year":"2024","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"1","key":"10.1016\/j.ajo.2025.08.034_bib0041","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.oret.2024.07.020","article-title":"Real-world 1-year outcomes of treatment-intensive neovascular age-related macular degeneration switched to Faricimab","volume":"9","author":"Sim","year":"2025","journal-title":"Ophthalmol Retina."},{"issue":"3","key":"10.1016\/j.ajo.2025.08.034_bib0042","article-title":"Quantifying fluid and function in suboptimal responders switched from an anti-vascular endothelial growth factor (VEGF) to Faricimab","volume":"16","author":"Sutter","year":"2024","journal-title":"Cureus"},{"issue":"10326","key":"10.1016\/j.ajo.2025.08.034_bib0043","first-page":"729","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet (British edition)."},{"issue":"9","key":"10.1016\/j.ajo.2025.08.034_bib0044","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1136\/bjophthalmol-2019-315021","article-title":"Changes in neovascular activity following fixed dosing with an anti-vascular endothelial growth factor agent over 52 weeks in the phase III VIEW 1 and VIEW 2 studies","volume":"104","author":"Moshfeghi","year":"2020","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.08.034_bib0045","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of Brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"issue":"20","key":"10.1016\/j.ajo.2025.08.034_bib0046","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and Bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ajo.2025.08.034_bib0047","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ophtha.2022.04.028","article-title":"MERLIN: phase 3a, multicenter, randomized, double-masked trial of Brolucizumab in participants with neovascular age-related macular degeneration and persistent retinal fluid","volume":"129","author":"Khanani","year":"2022","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2025.08.034_bib0048","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of Faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.08.034_bib0049","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/OPTH.S125676","article-title":"Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis","volume":"11","author":"Spooner","year":"2017","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2025.08.034_bib0050","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.survophthal.2018.02.004","article-title":"Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration","volume":"63","author":"Mantel","year":"2018","journal-title":"Surv Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2025.08.034_bib0051","doi-asserted-by":"crossref","first-page":"e757","DOI":"10.1111\/aos.13157","article-title":"Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration","volume":"94","author":"Munk","year":"2016","journal-title":"Acta Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2025.08.034_bib0052","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1136\/bjophthalmol-2020-317326","article-title":"Non-neovascular age-related macular degeneration with subretinal fluid","volume":"105","author":"Hilely","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.08.034_bib0053","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/aos.13864","article-title":"Baseline visual acuity as a prognostic factor for visual outcomes in patients treated with aflibercept for wet age-related macular degeneration: data from the INSIGHT study using the Swedish Macula Register","volume":"97","author":"L\u00f6vestam Adrian","year":"2019","journal-title":"Acta Ophthalmol."},{"issue":"1","key":"10.1016\/j.ajo.2025.08.034_bib0054","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1755-3768.2011.02268.x","article-title":"Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment","volume":"91","author":"Bloch","year":"2013","journal-title":"Acta Ophthalmol."},{"issue":"4","key":"10.1016\/j.ajo.2025.08.034_bib0055","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/IAE.0000000000003283","article-title":"Impact of fluid compartments on functional outcomes for patients with neovascular age-related macular degeneration: a systematic literature review","volume":"42","author":"Chaudhary","year":"2022","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.ajo.2025.08.034_bib0056","article-title":"A real-world study assessing the impact of retinal fluid on visual acuity outcomes in patients with neovascular age-related macular degeneration in Korea","volume":"12","author":"Kim","year":"2022","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ajo.2025.08.034_bib0057","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","article-title":"Randomized, double-masked, sham-controlled trial of Ranibizumab for neovascular age-related macular degeneration: PIER Study Year 1","volume":"145","author":"Regillo","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2025.08.034_bib0058","first-page":"2695","article-title":"A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration-the FALCON study","volume":"260","author":"Holz","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2025.08.034_bib0059","unstructured":"Novartis Pharmaceuticals. A 52-week, Two Arm, Randomized, Open-label, Multicenter Study Assessing the Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens for Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT04679935."},{"issue":"9","key":"10.1016\/j.ajo.2025.08.034_bib0060","doi-asserted-by":"crossref","DOI":"10.1097\/IAE.0000000000002670","article-title":"Ranibizumab treatment in treatment-naive Neovascular age-related macular degeneration: results from luminous, a global real-world study","volume":"40","author":"Holz","year":"2020","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.ajo.2025.08.034_bib0061","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/eye.2013.93","article-title":"Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial)","volume":"27","author":"Menon","year":"2013","journal-title":"Eye"},{"issue":"11","key":"10.1016\/j.ajo.2025.08.034_bib0062","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jamaophthalmol.2024.3828","article-title":"Sterile intraocular inflammation associated with Faricimab","volume":"142","author":"Cozzi","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2025.08.034_bib0063","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ajo.2024.08.008","article-title":"Severe intraocular inflammation after intravitreal injection of Faricimab: a single-site case series of six patients","volume":"269","author":"Ben Ghezala","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2025.08.034_bib0064","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaophthalmol.2024.0530","article-title":"Severe intraocular inflammation following Intravitreal Faricimab","volume":"142","author":"Thangamathesvaran","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2025.08.034_bib0065","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/IAE.0000000000004394","article-title":"Intraocular inflammation associated with Faricimab therapy: one-year real-world outcomes","volume":"45","author":"Montesel","year":"2025","journal-title":"Retina"},{"issue":"50","key":"10.1016\/j.ajo.2025.08.034_bib0066","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000036370","article-title":"Comparative efficacy and safety of Faricimab and other anti-VEGF therapy for age-related macular degeneration and diabetic macular edema: a systematic review and meta-analysis of randomized clinical trials","volume":"102","author":"Li","year":"2023","journal-title":"Medicine (Baltimore)"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425004416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425004416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T04:15:33Z","timestamp":1779855333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939425004416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":65,"alternative-id":["S0002939425004416"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.08.034","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Efficacy of Switching to Faricimab in Treatment Resistant Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.08.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}